Literature DB >> 30474540

Repurposing of Existing Drugs for the Bacterial Infections: An In silico and In vitro Study.

Yachika Kapoor1, Ruchika Sharma1, Anoop Kumar2,3.   

Abstract

BACKGROUND: The emergence of infectious diseases and its resistance to approved drugs is a global threat to human health. The incidence of infectious diseases is increasing day by day and expected to rise exponentially in next 2 decades. Thus, there is a need for new treatment modalities for the treatment of microbial infections.
METHODS: Thus, in the current investigation, we have explored the existing drugs [metformin (Anti-diabetic), propranolol (Anti-hypertensive) and amitriptyline (antidepressant)] for treatment of infectious diseases.
RESULTS: An in-silico result of current investigation has shown the good interaction of metformin, propranolol, and amitriptyline towards various targets (Beta-lactamase, Penicillin-binding proteins, Staphylokinase protein, Oxidoreductase protein, etc.) of gram positive and gram negative bacteria as that of internal ligand. Further, in-vitro results have shown that the antibacterial activity of metformin, propranolol, and amitriptyline against Bacillus pumilus, Pseudomonas aeruginosa and Staphylococcus aureus.
CONCLUSION: The parameters such as Microtiter assay: percentage growth retardation and bacterial growth kinetics, Minimum inhibitory concentration (MIC), Post-antibiotic assay and Biofilm formation have indicated the antibacterial potential of metformin, propranolol, and amitriptyline. However, before starting a clinical trial, complete safety and efficacy profile of drugs in the treatment of infectious diseases should be investigated. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  In silico; In vitro studies; Infectious diseases; bacterial infections; drug repurposition; metformin; propranolol.

Mesh:

Substances:

Year:  2020        PMID: 30474540     DOI: 10.2174/1871526519666181126094244

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  3 in total

1.  Expression and Functional Characterization of a Novel Antimicrobial Peptide: Human Beta-Defensin 118.

Authors:  Qian Lin; Kunhong Xie; Daiwen Chen; Bing Yu; Xiangbing Mao; Jie Yu; Junqiu Luo; Ping Zheng; Yuheng Luo; Hui Yan; Jun He
Journal:  Biomed Res Int       Date:  2020-11-09       Impact factor: 3.411

2.  Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice.

Authors:  Jan H Beumer; Jianxia Guo; Evan C Ray; Jonas Scemama; Robert A Parise; Berthony Deslouches; Jonathan D Steckbeck; Ronald C Montelaro; Julie L Eiseman
Journal:  Curr Rev Clin Exp Pharmacol       Date:  2021

3.  Bombyx mori gloverin A2 alleviates enterotoxigenic Escherichia coli-induced inflammation and intestinal mucosa disruption.

Authors:  Qian Lin; Guoqi Su; Aimin Wu; Daiwen Chen; Bing Yu; Zhiqing Huang; Yuheng Luo; Xiangbing Mao; Ping Zheng; Jie Yu; Junqiu Luo; Jun He
Journal:  Antimicrob Resist Infect Control       Date:  2019-11-26       Impact factor: 4.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.